Kiran Mazumdar Shaw's Journey: From Rejection to Revolutionizing Biotechnology
'Thank God' Kiran Mazumdar Shaw did not become a doctor: When Dr Devi Shetty shared a life lesson from Biocon founder's inspiring journey
The Economic TimesImage: The Economic Times
Kiran Mazumdar Shaw's journey from aspiring doctor to biotechnology pioneer illustrates how setbacks can lead to significant societal change. Devi Shetty, founder of Narayana Health, shared her story, highlighting how her failure to gain medical college admission redirected her efforts towards making affordable medicine accessible to millions, particularly in diabetes care.
- 01Kiran Mazumdar Shaw's rejection from medical school redirected her career path.
- 02She founded Biocon, transforming the biotechnology landscape in India.
- 03Her work has made insulin accessible to millions of diabetes patients.
- 04Devi Shetty emphasized the societal impact of her journey.
- 05Shaw's leadership continues with her successor, Claire Mazumdar.
Advertisement
In-Article Ad
Kiran Mazumdar Shaw, a prominent figure in biotechnology, initially aspired to be a doctor but faced disappointment when she did not gain admission to medical school. During a 2015 event at the Indian Institute of Management Bangalore, Dr. Devi Shetty, founder of Narayana Health, reflected on how this setback led Shaw to shift her focus from treating individual patients to addressing broader healthcare issues. This redirection resulted in the establishment of Biocon, a company that has significantly impacted the availability of affordable medicines, particularly insulin for diabetes patients. Shetty remarked that had Shaw pursued a traditional medical career, her influence would have been limited to a small number of patients. Instead, her entrepreneurial journey has transformed the biotechnology sector in India, benefiting millions. Shaw, who began her venture in 1978, has built Biocon into a global player in biotech, emphasizing accessible healthcare. With an estimated net worth of βΉ30,000 crore (approximately $3.6 billion USD), she continues to lead Biocon while preparing her successor, Claire Mazumdar, who holds impressive academic credentials in biological engineering and cancer biology.
Advertisement
In-Article Ad
Kiran Mazumdar Shaw's work has improved healthcare access for millions of patients in India, particularly those with diabetes.
Advertisement
In-Article Ad
Reader Poll
Do you believe setbacks can lead to greater opportunities in life?
Connecting to poll...
More about Biocon
Biocon Shares Rise Following Kiran Mazumdar-Shaw's Niece Named as Successor
The Economic Times β’ May 5, 2026
Kiran Mazumdar Shaw's Journey: From Rejection to Revolutionizing Healthcare
The Economic Times β’ May 5, 2026
Claire Mazumdar Positioned as Future Leader of Biocon Amid Transition
The Economic Times β’ May 5, 2026
Read the original article
Visit the source for the complete story.

